Encapsulated human primary myoblasts deliver functional hFIX in hemophilic mice

Journal of Gene Medicine

Volumn 9, Issue 11, 2007, Pages 1002-1010

  Wen, Jianping ^a   Xu, Nong ^a   Li, Anna ^a   Bourgeois, Jacqueline ^a   Ofosu, Frederick A ^a   Hortelano, Gonzalo ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Alginate; Factor IX; Gene therapy; Hemophilia B; Microcapsules; Myoblasts

Indexed keywords

ALGINIC ACID; BLOOD CLOTTING FACTOR 9; RETROVIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DETECTION; ARTICLE; BLEEDING TIME; CELL BASED GENE THERAPY; CELL VIABILITY; COMBINED IMMUNODEFICIENCY; CONTROLLED STUDY; EMBRYO; FEASIBILITY STUDY; GENETIC TRANSDUCTION; GENETIC TRANSFECTION; HEMOPHILIA B; HUMAN; HUMAN CELL; HUMAN TISSUE; MICROCAPSULE; MOLECULAR CLONING; MOUSE; MYOBLAST; NONHUMAN; NONOBESE DIABETIC MOUSE; NONVIRAL GENE DELIVERY SYSTEM; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; SCID MOUSE;

ANIMALS; CAPSULES; CELL SURVIVAL; DRUG DELIVERY SYSTEMS; FACTOR IX; HEMOPHILIA B; HUMANS; MICE; MYOBLASTS; TREATMENT OUTCOME;

MUS;

EID: 36148959328     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1098     Document Type: Article

References (33)

1. Sadler JE, Davie EW. Hemophilia A, hemophilia B, and von Willebrand's disease. In The Molecular Basis of Blood Diseases, Nienhuis AW, Leder P, Majerus PW (eds). W.B. Saunders: New York, 1987; 575-598.
2. Giangrande PL. Blood products for hemophilia: past, present and future. BioDrugs 2004; 18: 225-234.
3. Carcao MD, Aledort L. Prophylactic factor replacement in hemophilia. Blood Rev 2004; 18: 101-113.
4. Ragni MV. Hemophilia gene transfer: comparison with conventional protein replacement therapy. Semin Thromb Hemost 2004; 30: 239-247.
5. Dimichele D, Miller FG, Fins JJ. Gene therapy ethics and haemophilia: an inevitable therapeutic future? Haemophilia 2003; 9: 145-152.
6. Manno CS, Chew AJ, Hutchison S, et al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 2003; 101: 2963-2972.
7. Gomez-Vargas A, Hortelano G. Transplants for hemophilia. In Cell Transplants: from Laboratory to Clinic. Halberstadt C, Emerich D (eds). Elsevier: Oxford, 2006; in press.
8. Roth DA, Tawa NE Jr, O'Brien JM, et al. Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A. N Engl J Med 2001; 344: 1735-1742.
9. Orive G, Hernandez RM, Gascon AR, et al. Cell encapsulation: promise and progress. Nat Med 2003; 9: 104-107.
10. Orive G, Hernández RM, Gascón AR, et al. History, challenges and perspectives of cell microencapsulation. Trends Biotechnol 2003; 22: 87-92.
11. Calafiore R, Basta G. Luca G, et al. Standard technical procedures for microencapsulation of human islets for graft into nonimmunosuppressed patients with type 1 diabetes mellitus. Transplant Proc 2006; 38: 1156-1157.
12. Haque T, Chen H, Ouvang W. et al. In vitro study of alginatechitosan microcapsules: an alternative to liver cell transplants for the treatment of liver failure. Biotechnol Lett 2005; 27: 317-322.
13. Hortelano G, Al-Hendy A, Ofosu FA, et al. Delivery of human factor IX in mice by encapsulated recombinant myoblasts: a novel approach towards allogeneic gene therapy of hemophilia B. Blood 1996; 87: 5095-5103.
14. Snyder RO, Miao C, Meuse L, Tubb J, Donahue BA. Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors. Nat Med 1999; 5: 64-70.
15. Gomez-Vargas A, Rosenthal KL, McDermott MR, Hortelano G. Continuous antigenic stimulation system (CASS) as a new immunization strategy. Vaccine 2004; 22: 3902-3910.
16. Hortelano G, Wang L, Xu N. et al. Sustained and therapeutic delivery of factor IX in nude haemophilia B mice by encapsulated C2C12 myoblasts: concurrent tumourigenesis. Haemophilia 2001; 7: 207-214.
17. Wen J, Ofosu FA, Hortelano G. Encapsulated primary myoblasts deliver sustained and therapeutic levels of human factor IX to hemophilic mice. J Gene Med 2005; 8: 362-369.
18. Yao SN, Kurachi K. Expression of human factor IX in mice after injection of genetically modified myoblasts. Proc Natl Acad Sci U S A 1992; 89: 3357-3361.
19. Roman M, Axelrod JH, Dai Y, et al. Circulating human or canine factor IX from retrovirally transduced primary myoblasts and established myoblast cell lines grafted into murine skeletal muscle. Somat Cell Mol Genet 1992; 18: 247-258.
20. Lawson MA, Purslow PP. Differentiation of myoblasts in serum-free media: effects of modified media are cell line-specific. Cells Tissues Organs 2000; 167: 130-137.
21. Springer ML, Blau HM. High-efficiency retroviral infection of primary myoblasts. Somat Cell Mol Genet 1997; 23: 203-209.
22. Wang L, Zoppe M, Hackeng TM, et al. A factor IX-deficient mouse model for hemophilia B gene therapy. Proc Natl Acad Sci USA 1997; 94: 11563-11566.
23. Chuah MKL, Collen D, VandenDriessche T. Clinical gene transfer studies for hemophilia A. Semin Thromb Hemost 2004; 30: 249-256.
24. High KA. Clinical gene transfer studies for hemophilia B. Semin Thromb Hemost 2004; 30: 257-267.
25. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al. LMO2-associated associnal T cell proliferation in two patients
26. Manno CS, Pierce GF, Arrunda VR, et al Successful transduction of liver hemophilia by A. Factor IX and limitations imposed by the host immune response. Nat Med 2006; 12: 342-347.
27. Vilquin JT. Myoblast transplantation: clinical trials and perspectives. Acta Myol 2005; 24: 119-127.
28. Opie SR, Dib N. Surgical and catheter delivery of autologous myoblasts in patients with congestive heart failure. Nat Clin Pract Cardiovasc Med 2006; 3(Suppl 1): S42-45.
29. Mouly V, et al. Myoblast transfer therapy: is there any light at the end of the tunnel? Acta Myol 2005; 24: 128-133.
30. Kollet O, Peled A, Byk T, et al. Beta 2 microglobulin-deficient (B2m(null)) NOD/SCID mice are excellent recipients for studying human stem cell function. Blood 2000; 95: 3102-3105.
31. Li AA, MacDonald NC, Chang PL. Effect of growth factors and extracellular matrix materials on the proliferation and differentiation of microencapsulated myoblasts. J Biomater Sci Polym Ed 2003; 14: 533-549.
32. Hewitson TD, Martic M, Kelynack KJ, et al. Thrombin is a pro-fibrotic factor for rat renal fibroblasts in vitro. Nephron Exp Nephrol 2005; 101: e42-49.
33. Yan H, Lu. D, Rivkees SA. Lysophosphatidic acid regulates the proliferation and migration of of olfactory ensheathing cells in vitro. Glia 2003; 44: 26-36.